Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non–Small Cell Lung Cancer in US Clinical Practice

Mary K. Nesline,Tyler Knight,Sam Colman, Kayshap Patel

Clinical Therapeutics（2020）

引用 12|浏览10

暂无评分

摘要

•Most NSCLC patients do not benefit from checkpoint inhibitor (CPI) immunotherapy.•Minimum recommended molecular testing for NSCLC treatment selection is underutilized.•NSCLC CPI treatment incurs significantly higher medical resource utilization and costs.•Comprehensive genomic and immune profiling can decrease futile CPI care in NSCLC.

查看译文

关键词

biomarkers,costs,immunotherapy,medical resource use,non–small cell lung cancer,real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要